Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28146
a fee-bearing, terminable, indivisible, non-transferable, right and license, with the right to grant sublicenses, to use and consume the Deliverables solely as necessary to conduct studies within the Research Field; and a fee-bearing, royalty-bearing, terminable, indivisible, non-transferable, exclusive right and license, with the right to grant sublicenses, to sell Licensed Human Therapeutic Products in the Territory within the Exclusive Field.
The Licensor's antibody-drug conjugate platform technology is based on unique multivalent, cleavable linkers that allow drugs tethered to the antibody to be released intracellularly or extracellularly upon binding of the antibody to the target cell. and the technology platform allows multiple drugs to be attached per targeting antibody, and to release the drugs in their original form without modification of the drug.
IPSCIO Record ID: 28877
– a terminable, indivisible, non-transferable, right and license, with the right to grant sublicenses, to use and consume the Deliverables solely as necessary to conduct studies within the Research Field; and,
– a terminable, indivisible, non-transferable, exclusive right and license, with the right to grant sublicenses, to sell Licensed Human Therapeutic Products in the Territory within the Exclusive Field. Licensor shall not assert any Licensor Patent Rights against Licensee or any permitted sublicensee so long as such parties exercise the rights in the preceding sentence as permitted.
Licensor owns technology and patent rights in the field of antibody-drug conjugates.
Licensed Product shall mean an antibody-drug conjugate therapeutic product containing [FZD7 monoclonal antibody and either 2-(4-phenylcyclohexyl)-5-(l',l'-dimethylheptyl)-resorcinol (0-1663) or 2-((3,4-bis(benzyloxy)benzyl)amino)ethan-1-ol (XRK3 or XIE3-P62) or 0-1663 and Taxol], that if made, used, sold, offered for sale or imported by OXIS or its Affiliate absent the license granted hereunder would infringe a Valid Claim of the Licensed Patent Rights, or otherwise use or incorporate the Licensed Technology Know-How Rights. For convenience, the chemical structures and alternative names for [0-1663, XIE3-P62 and Taxol] Taxol or Placitaxel.
Licensed Human Therapeutic Product shall mean a Licensed Product that is synthesized for and
intended for in vivo therapeutic use in humans.
The patent is titled Methods and Compositions for targeted Therapies.
Under the terms of the agreement, the Licensor will develop three antibody-drug conjugates product candidates which contain the Licensee's lead drug candidates OXS-2175 and OXS-4235.
IPSCIO Record ID: 240612
'ADCs utilize the targeting ability of monoclonal antibodies to deliver potent, cell-killing payloads to specific cells. ADC technology employs synthetic, highly potent drugs that can be attached to antibodies through proprietary linker systems. The linkers are designed to be stable in the bloodstream but to release the drug payload under specific conditions once inside target cells, thereby sparing non-target cells many of the toxic effects of traditional chemotherapy.
IPSCIO Record ID: 307594
The companies will partner to develop Licensorâ€™s next-generation bispecific antibody programs, epcoritamab (DuoBodyÂ®-CD3xCD20), DuoHexaBodyÂ®-CD37 and DuoBody-CD3x5T4. The collaboration combines Licensorâ€™s world-class discovery and development engine and next-generation bispecific antibody therapeutic candidates with Licenseeâ€™s deep clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers. Licensorâ€™s DuoBody-CD3 technology engages and directs cytotoxic T cells selectively to tumors to elicit an immune response towards malignant tumor cells. Licenseeâ€™s ADC technology allows the delivery of a therapeutic toxin directly to cancer cells while sparing normal, healthy cells, providing for a more targeted, less toxic treatment approach.
Licensor is a biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Licensors technology base consists of validated and proprietary next generation antibody technologies – the DuoBodyÂ® platform for generation of bispecific antibodies, the HexaBodyÂ® platform, which creates effector function enhanced antibodies, the HexElectÂ® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBodyÂ® platform, which enhances the potential potency of bispecific antibodies through hexamerization.
Licensee has a clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers.
IPSCIO Record ID: 263763
Licensor grants to Licensee, to the extent Licensor is legally able to do so, a non-exclusive, sublicensable, license in the Territory under such issued letters patent for Licensee to develop, make, have made, use, sell, offer for sale or import Compounds and Products in the Territory.
For the Covenants/Companion Diagnostic, Licensor grants a non-exclusive license, with the right to grant sublicenses, under Licensor Patent Rights, Licensor Know-How, and Companion Diagnostic Trademarks to market and promote the Companion Diagnostic in the Field in the Territory for use in connection with the Product and use the Companion Diagnostic in any way necessary or reasonably useful in order for Licensee to exercise the license granted by Licensor.
This agreement is to develop and commercialize a novel investigational therapeutic candidate vintafolide (EC145).
Vintafolide is a proprietary, injectable, conjugate consisting of folate (vitamin B9) linked to a potent vinca alkaloid chemotherapy agent, desacetylvinblastine monohydrazide (DAVLBH).
Etarfolatide is a folate-targeted molecular imaging agent that is being developed as a noninvasive method to identify tumors that over-express folate receptors.
Product(s) means any pharmaceutical or biological preparation.
Vintafolide is designed to preferentially target the chemotherapy agent to fast growing cancer cells that actively take up folate via the folate receptor. The folate receptor is expressed in a wide variety of cancers including ovarian, NSCLC, breast, colon and kidney.